You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Developing a novel platform for rapid identification of drug targets and anti-targets
SBC: Truvitech, LLC Topic: NCATSPROJECT SUMMARY Drugs act by altering the activities of particular componentstargetswithin a cell or organismThusdrug discovery campaigns begin by identifying a targetfollowed by screening this target with compounds to identify leads that can be developed into a drugUnfortunatelyidentifying effective drug targets for a given diseaselet alone for individual patientse gin highly heterogeneous cancer ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Measuring Infant Pain Objectively using Sensor Fusion and Machine Learning Algorithms
SBC: AUTONOMOUS HEALTHCARE INC Topic: R41Newborns are routinely and frequently exposed to pain during Neonatal ICUNICUcarePain assessments in neonates are difficultlabor intensivesubjective and unreliableoften resulting in excessive or inadequate analgesiaOur overall objective is to measure infant pain objectivelyreliablyand in real timeWe will extract pain related information from multiple non invasive sensorsdevelop a sensor fusion fra ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.
SBC: ARCHER PHARMACEUTICALS, INC. Topic: NIAPathological hallmarks of Alzheimerandapos s diseaseADinclude extracellular deposits of Apeptidesintraneuronal aggregates of abnormally phosphorylated tau protein and neuroinflammationMost proposed AD disease modifying therapies have focused on strategies that reduce brain Aamyloid or tau pathological accumulationHoweversuch approaches have been unsuccessful in late stage AD clinical trials and ma ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
A ratcheting prosthetic partial finger using advanced rapid manufacturing technology
SBC: POINT DESIGNS, LLC Topic: NICHDThe Point PartialA Ratcheting Prosthetic Partial FingerUsing Advanced Rapid Manufacturing Technology Project SummaryAbstract The goal of the proposed project is to develop a purely mechanicalratcheting prosthetic partial fingerthe Point Partialwhichhas an industry leading strength to weight ratiocan be operated unilaterallyone handedoffers anatomical rotation and flexion around the patient s proxi ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
TFEB Activator for Alzheimer's Disease Therapy
SBC: BRILLIANT BIOSCIENCES INC. Topic: NIAOne in ten of the persons ageare affected by Alzheimer s diseaseADcausing enormous social and economic burden to the United StatesTo date only five medications have been approved by the FDA for the treatment of the symptoms of ADbut none of them slows or stops the disease progressionWith the recent repeated failures of AD drugs on thesecretase inhibitorsthe need for an effective AD drug became eve ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
A universal eye drop adherence monitor to measure and improve adherence to ocular medications
SBC: Universal Adherence LLC Topic: NProject Summary Abstract Universal Adherence is an emerging medical device company dedicated to improving adherence to ocular medications through innovative technical solutionsOur proposed Devers Drop DeviceDwill accurately track when a patient removes an eye drop bottle capcommunicate usage data wirelessly to a database that researchers can accessand send alerts to patients when a medication is d ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Enhancement of the Beneficial Effects of Mesenchymal Stem Cell (MSC) Treatment by the Caveolin-1 Scaffolding Domain Peptide (CSD)
SBC: LUNG THERAPEUTICS INC Topic: NHLBIAbstract Systemic sclerosissclerodermaSScis a chronic connective tissue disease in which lung fibrosis is the most frequent cause of deathSSc and idiopathic pulmonary fibrosis are the two most common disease that falls under the interstitial lung diseasesILDa grouping of devastating diseases in which lung fibrosis leads to progressive shortness of breatha very poor quality of lifeand death within ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Building an evidentiary case for circulating GHBP as a biomarker for drug-associated stunting of growth
SBC: ReveraGen BioPharma, Inc. Topic: NICHDThere is increasing interest in the use of biomarkers in clinical drug developmentwith much of thest Century Cures Act focused on encouraging this approachIdeallybiomarkers could provide and acute and objective read out of drug mechanism of actionpharmacodynamic biomarkersor prediction of later clinical benefit or harmsurrogate outcome measureHoweververy few biomarkers have been validated for rout ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Nanofiber Expanded CD34+ Stem Cells for Osteoporosis Therapy
SBC: HNB Therapeutics LLC Topic: NIASummary Glucocorticoid induced osteoporosis is the most common cause of secondary osteoporosisand the primary cause before ageIt affects overof the general populationwhereinare womenIn postmenopausal women and men agedand overtreatment would be recommended in at least half based on theAmerican College of Rheumatology guidelinesAdult stem cells are a promising class of regenerative cellssome lineag ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Technology for the non-invasive surveilance of post-traumatic compartment syndrome
SBC: Myolex Inc Topic: NIAMSPROJECT SUMMARYAcute compartment syndromeACSremains one of the most devastating and often overlooked traumatic musculoskeletal disorders in clinical practiceIn this conditionpressure increases in one of the body s spacelimited compartmentsdue most commonly to direct trauma or bone fractureresulting ultimately in an ischemic injury to all of the compartment s contentsincluding muscle and nerveOnce ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health